Reverse Mortgage vs. Home-Equity Agreement at 70: How to Decide
A 70-year-old single homeowner weighs two ways to tap home equity. Here's what each option really means for long-term financial security.
For older homeowners living on fixed incomes, the equity locked inside a paid-down home can look like a lifeline — but choosing the wrong instrument to access it can create serious financial complications down the road. The dilemma facing one 70-year-old single homeowner, as posed to MarketWatch, cuts to the heart of a decision millions of aging Americans will eventually confront: a reverse mortgage or a home-equity agreement.
A reverse mortgage allows homeowners aged 62 and older to borrow against their home's value without making monthly payments, with the loan balance due when the borrower sells, moves out, or dies. For someone who doubts they will reach 80 — and therefore has a shorter planning horizon — a reverse mortgage's deferred repayment structure can seem appealing. The longer you live, however, the more interest compounds, potentially eroding the estate left to heirs.
Read more At 33, Relocating to Raise a Niece: The Financial Trade-Offs →
A home-equity agreement, by contrast, is not a loan at all. In exchange for a lump-sum payment today, an investor takes a share of the home's future appreciation or value at sale. There are no interest charges and no monthly payments, but if the home rises significantly in value, the homeowner — or their estate — surrenders a meaningful slice of that gain. For someone with a shorter expected time horizon, the upside-sharing cost could be relatively modest, making this option worth serious analysis.
The calculus here is genuinely personal. Health expectations, estate planning goals, liquidity needs, and local real estate market trajectory all shape which instrument delivers better value. A shorter life expectancy arguably reduces the compounding-interest risk of a reverse mortgage while also limiting the appreciation exposure that makes a home-equity agreement costly. Neither product is inherently superior — both carry fees, both affect heirs, and both deserve scrutiny from a fee-only financial advisor before any commitment is made.
Continue reading at MarketWatch.com
